Dare Bioscience, Inc. Common Stock (DARE)
Dare Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for women’s reproductive health and sexual wellness. The company's pipeline includes treatments for fertility, contraception, and other gynecological conditions, aiming to address unmet medical needs in women's health.
Company News
Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.
Daré Bioscience announced a webinar on August 6, 2025, introducing DARE to PLAY™, a novel sildenafil cream designed to improve female sexual arousal, targeting prescription availability in Q4 2025.
Dare Bioscience, a biopharmaceutical company focused on women's health, has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock achieved the necessary closing bid price of $1.00 or more per share over 10 consecutive trading sessions.
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
HC Wainwright & Co. has decided to maintain its Buy rating of Dare Bioscience (NASDAQ:DARE) and raise its price target from $6.00 to $7.00. Shares of Dare Bioscience are trading up 2.84% over the last 24 hours, at $0.96 per share. A move to $7.00 would account for a 631.99% increase from the current share price. About Dare Bioscience Dare Bioscie...